Human Apolipoprotein C3 (APOC3) Protein
208€ (10 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human Apolipoprotein C3 (APOC3) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx166434
tested applications
WB, SDS-PAGE
Description
Human Apolipoprotein C3 Protein is a recombinant Human protein expressed in E. coli.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Apolipoprotein C3 (APOC3) |
| Host | E. coli |
| Origin | Human |
| Conjugation | Unconjugated |
| Observed MW | Molecular Weight: Calculated MW: 38.8 kDa Observed MW (SDS-PAGE): 26, 33, 34 kDa Possible reasons why the actual band size differs from the predicted band size: 1. Splice variants. Alternative splicing may create different sized proteins from the same gene. 2. Relative charge. The composition of amino acids may affect the charge of the protein. 3. Post-translational modification. Phosphorylation, glycoslyation, methylation etc. may affect the band size. 4. Post-translational cleavage. Many proteins are synthesised as pro-proteins, and then cleaved to give the active form. 5. Polymerisation of the target protein. Dimerisation, multimerisation etc. will increase the band size observed. Concentration: Prior to lyophilization: 700 µg/ml Sequence Fragment: Ser21-Ala99 Tag: N-terminal His tag and GST tag |
| Expression | Recombinant |
| Purity | > 95% |
| Size 1 | 10 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 500 µg |
| Form | Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in 10 mM PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in 10 mM PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex. |
| Tested Applications | WB, SDS-PAGE |
| Buffer | Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 5% Trehalose. |
| Availability | Shipped within 5-7 working days. |
| Storage | Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P02656 |
| Gene ID | 345 |
| Alias | APOC3, APOCIII, HALP2, apolipoprotein C3, Apo-C3, ApoC-3,apo-CIII, and apolipoprotein C-III |
| Background | Protein APOC3 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
APOC3 is a critical regulator of triglyceride-rich lipoprotein (TRL) metabolism, primarily associated with VLDL, HDL, and chylomicrons. APOC3 inhibits lipoprotein lipase (LPL) and hepatic uptake of remnant lipoproteins by interfering with the binding of TRLs to heparan sulfate proteoglycans (HSPG) and the low-density lipoprotein receptor (LDLR). Elevated APOC3 levels are strongly associated with hypertriglyceridemia, atherogenic dyslipidemia, and increased risk of cardiovascular disease. APOC3 expression is regulated by dietary factors, insulin, and nuclear receptors such as PPAR-alpha. Loss-of-function mutations in the APOC3 gene result in lower plasma triglycerides and reduced cardiovascular risk, highlighting its potential as a therapeutic target for lipid disorders. APOC3 also modulates inflammatory responses and has been implicated in non-alcoholic fatty liver disease (NAFLD), where elevated levels contribute to hepatic lipid accumulation. Pharmacological inhibitors of APOC3, such as antisense oligonucleotides, are being developed to lower plasma triglycerides and improve lipid profiles in hyperlipidemic patients.
Related Products
Human APOC3 (Apolipoprotein C-III) ELISA Kit
Ver Producto
Recombinant Human APOC3
Ver Producto